BSE filing, NSE: SWASTIVI. Summary written from the filing by ALFA Finder's alert engine.
Swasti Vinayaka Synthetics Ltd: key numbers
- Share price
- ₹3.21
- Market cap
- ₹28.89 Cr
- Revenue (annual)
- ₹32.03 Cr
- Net profit (annual)
- ₹3.05 Cr
- P/E (TTM)
- 8.6×Sector 49.5×
- Promoter holding
- 51.00%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Swasti Vinayaka Synthetics Ltd
All →Swasti Vinayaka Synthetics Other Announcement
Swasti Vinayaka Synthetics Ltd has submitted its quarterly shareholding pattern statement for the period ended September 30, 2026. This is a routine regulatory compliance filing.
Swasti Vinayaka Synthetics Annual General Meeting
Swasti Vinayaka Synthetics Ltd held its 44th Annual General Meeting on September 29, 2026. Shareholders approved routine business items, director appointments, and related party transactions.
Swasti Vinayaka Synthetics Other Announcement
Swasti Vinayaka Synthetics informed shareholders of the web-link for accessing the FY 2025-26 Annual Report, as per Regulation 36(1)(b).
Swasti Vinayaka Synthetics Annual Report
Swasti Vinayaka Synthetics Ltd has submitted its Annual Report for the financial year ended March 31, 2026, as required under SEBI LODR regulations.
Swasti Vinayaka Synthetics Annual General Meeting
Swasti Vinayaka Synthetics Limited has issued the notice for its 44th Annual General Meeting scheduled for September 29, 2026, to address financial statements and director appointments.
Swasti Vinayaka Synthetics Annual General Meeting
Swasti Vinayaka Synthetics Ltd will hold its 44th Annual General Meeting on September 29, 2026. The company also approved the Board's Report for FY 2025-26.
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.